ENO1 and glioma: In the current study, we found that glioma cell lines that have either homozygous (D423) or heterozygous (D502, U343) deletions of ENO1 are selectively more sensitive to the enolase inhibitor POMHEX than are ENO1 rescued (D423 ENO1) and wild-type cells (LN319) (Fig. 1 a-c).